Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma

  • Technology appraisal guidance
  • TA269
  • Published: 
  • Last updated: 
Download guidance (PDF)

1 Guidance

1.1 Vemurafenib is recommended as an option for treating BRAF V600 mutation‑positive unresectable or metastatic melanoma only if the manufacturer provides vemurafenib with the discount agreed in the patient access scheme.